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Abstract Real-time polymerase chain reaction (PCR)
represents a favourable option for the detection of hepatitis
C virus (HCV). A real-time reverse transcriptase PCR (RT-
PCR) assay was developed as a qualitative diagnostic
screening method for the detection of HCV using the ABI
PRISM® 7500 Sequence Detection System. The primers
and probe were designed to target the 5′-untranslated region
of the hepatitis C viral genome. A second heterologous
probe assay was developed for the detection of the
haemagglutinin gene of phocine distemper virus (PDV)
and was used as an internal control. A semi-automated
HCV extraction method was also implemented using the
ABI PRISM™ 6100 Nucleic Acid PrepStation. The HCV
assay was optimised as a qualitative singleplex RT-PCR
assay with parallel testing of the target and internal control.
The assay results (n=200) were compared to the COBAS
AMPLICOR™ HCV Test v2.0 assay. The assay demon-
strated a high rate of sensitivity (99%), specificity (100%)
and an acceptable limit of detection (LOD) of 100 IU/ml.
The development of a qualitative multiplex assay for the
simultaneous detection of HCV and internal control
indicates the same high rates of sensitivity and specificity.
This sensitive real-time assay may prove to be a valuable
method for the detection of HCV.
Introduction
Hepatitis C virus (HCV) is responsible for most cases of
blood-borne hepatitis and is the leading cause of chronic
liver disease worldwide, with a global prevalence of
hepatitis C infection of approximately 2% [1]. Traditional
laboratory assays for the diagnosis and management of
HCV infection include serological tests to detect and
classify antibody response and to determine the HCV
RNA genotype. Many limitations are, however, associated
with the serological diagnosis of hepatitis C. These
limitations include a requirement for confirmation by other
assays (e.g. immunoblots), reduced specificity in low-risk
populations, reduced sensitivity in cases of early infection
and immunosuppression, and, most importantly, the inability
to distinguish between resolved and chronic infection [2, 3].
Reverse transcriptase polymerase chain reaction (RT-PCR)
is considered to be the “gold standard” for the detection
of viral genomic RNA in serum or plasma. The detection
of RNA exclusively demonstrates active viral infection
[3]. Therefore, unlike serology, HCV RNA testing can be
used for the diagnosis of acute hepatitis before seroconver-
sion, in seronegative patients with immune deficiency and
for investigating congenital HCV infection. HCV RNA
detection is also useful for confirming indeterminate
serological results and for monitoring response to treatment
[3, 4].
In the last ten years, many commercial nucleic acid
amplification assays for qualitative and quantitative HCV
detection have become available. However, these methods
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can be laborious and time-consuming. Automated technolo-
gies such as real-time PCR represent a more favourable option
for accurate qualitative and quantitative hepatitis C detection.
Unlike conventional, end-point PCR, where amplicon ampli-
fication and detection involve separate steps and run the risk of
cross-contamination between samples and/or PCR product
and where sensitivity is often limited by the resolution of the
detection method (e.g. agarose gel electrophoresis), real-time
PCR systems offer rapid combined amplification and real-
time, probe-based detection of amplicons in a closed
automated system. However, whilst the commercial real-time
PCR assays are appealing, the cost may prohibit their
introduction into routine diagnostic laboratories. Nevertheless,
many open-channel real-time PCR platforms are now avail-
able. These flexible systems function as analytical platforms
that allow full customisation of the diagnostic assay design.
Despite the advantages offered by real-time detection
platforms, sample preparation remains the major rate-
limiting step. Conventional manual nucleic acid extraction
methods are time-consuming, labour-intensive and suscep-
tible to contamination. Fully automated sample preparation
systems are increasingly available to accompany real-time
platforms. These systems offer the rapid isolation of nucleic
acids on a high-throughput scale. Such systems are,
however, costly. Semi-automated nucleic acid preparation
systems, such as the ABI PRISM™ 6100 Nucleic Acid
PrepStation (Applied Biosystems, Foster City, CA), could
provide a more cost-effective alternative. This system is a
small, bench-top instrument comprised of a programmable
vacuum manifold and a 96-well filtration plate, which uses
solid-phase extraction chemistry for the purification of
DNA or RNA from a range of sample types. Development
of a combined ABI 6100 HCV extraction method with a
real-time ABI 7500 RT-HCV PCR assay may, therefore,
facilitate the rapid and accurate detection of HCV.
Materials and methods
A total of 650 serum samples were used for the develop-
ment and optimisation of the RT-PCR assay. A further 200
samples were used in a clinical trial. All samples were
collected from randomly selected patients attending the
hepatology clinic at St. James’s Hospital, Dublin, Ireland.
Samples were separated and frozen at −20°C within 4 h of
collection. A 200-μl aliquot of serum was removed and
tested for HCV-RNA by the COBAS AMPLICOR™ HCV
Test v2.0 assay (Roche Diagnostics GmbH, Mannheim,
Germany). A 500-μl aliquot of serum was removed and
tested using the ABI PRISM® 7500 Sequence Detection
System (Applied Biosystems, Foster City, CA).
A dilution series of the WHO Second International
Standard 2003 for HCV RNA (National Institute for
Biological Standards and Control (NIBSC), code 96/798,
Hertfordshire, UK) was used to determine the lower limit of
detection (LOD) of the RT-PCR assay. The HCV RNA
Genotype Panel for Nucleic Acid Amplification Techniques
(NIBSC, code 02/202, Hertfordshire, UK) and the Quality
Control for Molecular Diagnostics (QCMD) 2002 and 2004
HCV Proficiency Panels (QCMD, Glasgow, Scotland) were
also used to assess assay performance.
Template RNA was extracted from 500 μl of serum
samples using the ABI PRISM™ 6100 Nucleic Acid
PrepStation (Applied Biosystems). A 70-μl aliquot of
master mix consisting of 100 μg of proteinase K (Applied
Biosystems), 25 μg of polyadenylic acid (Sigma-Aldrich
IRL Ltd., Dublin, Ireland) and 10 μl of phocine distemper
virus (PDV) internal control (IC) was added to the samples.
The PDV IC was kindly supplied as a 1,000× stock cell
culture by Dr. Hubert Niesters, Department of Virology,
Erasmus MC, University Medical Center, Rotterdam, the
Netherlands [5]. Samples were mixed and then incubated at
room temperature for 1 h. The lysates were applied to the
ABI PRISM™ 6100 Nucleic Acid PrepStation and vacu-
um-based wash and elution steps were performed according
to the manufacturer’s instructions.
Prior to use, the ABI 6100 extraction protocol was
evaluated by comparison with the QIAamp® UltraSens™
virus extraction method (QIAGEN GmbH, Hilden, Ger-
many). The manual extraction was performed according to
the manufacturer’s instructions using a 500-μl start volume.
Forty serum samples were extracted by both methods.
All RNA eluates were converted to cDNA using the
High-Capacity cDNA Archive Kit (Applied Biosystems).
The cDNA conversion was performed according to the
manufacturer’s instructions with the following modifica-
tions. In the preparation step, the total reaction volume was
optimised to 50 μl and RT reaction conditions were
optimised to 25°C for 10 min, followed by 37°C for 1 h.
HCV-specific primers and probes were selected using
Primer Express Software™Version 2.0 (Applied Biosystems)
(Table 1). The HCV-specific primer set, HCV-F (5′-
AGCGTCTAGCCATGGCGTT-3′) and HCV-R (5′-
GCAAGCACCCTATCAGGCAGT-3′) was designed to gen-
erate a 238-bp amplicon. The probe (5′-TCTGCGGA
ACCGGTGAGT-MGB-3′) was designed as a 5′-FAM-
labelled minor groove binding (MGB) hybridisation probe.
The PDV haemagglutinin gene (GenBank accession
#AF479274) was selected as the target for the PDV IC
primer–probe set, details of which were supplied by Dr.
Niesters (personal communication). The original primer set,
PDV-F (5′-GGTGGGTGCCTTTTACAAGAAC-3′) and
PDV-R (5′-ATCTTCTTTCCTCAACCTCGTCC-3′), was
modified to generate an 83-bp amplicon. The probe (5′-
ATGCAAGGGCCAATT-MGB-3′) was re-designed as a 5′-
VIC-labelled MGB hybridisation probe (Table 2).
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The assay was designed as a qualitative singleplex RT-
PCR assay with parallel detection of HCV and PDV in
separate wells. Both the HCV and PDV reactions were
optimised to a final reaction volume of 50 μl, containing
10 μl of cDNA and 40 μl of PCR mixture. This PCR
mixture contained 25 μl of TaqMan® 2× Universal PCR
Master Mix (Applied Biosystems), 0.3 μM of HCV-specific
primers and 0.25 μM of HCV-specific MGB probe, or
0.3 μM of PDV-specific primers and 0.25 μM of PDV-
specific MGB probe. Primer and probe concentrations were
optimised for both reactions using “matrix guidelines” from
Applied Biosystems. The amplification protocol for both
gene targets included an initial denaturation step at 95°C for
10 min, followed by 50 cycles at 95°C for 15 s and 60°C
for 1 min.
Following the optimisation of a singleplex assay, efforts
were made to develop the assay into a qualitative multiplex
format. The PDV amplification reaction was optimised as a
primer-limited assay using the “limiting primer matrix”
(Applied Biosystems 2001). For the multiplex assay, 10 μl
of cDNAwas added to 40 μl of reaction mixture containing
25 μl of TaqMan® Universal PCR Master Mix, 0.3 μM of
HCV-specific primers, 0.1 μM of PDV-specific primers and
0.25 μM of both HCV-specific and PDV-specific MGB
probes.
The LOD for the HCV assay was determined using a
dilution series of the WHO Standard, covering a range from
10 IU/ml to 10,000 IU/ml. The sensitivity of the assay was
also monitored by testing the external QCMD 2002 and
2004 HCV Proficiency Panels. Genotype specificity of the
Table 2 Multiple sequence alignment for phocine distemper virus (PDV)-specific primer–probe set for the haemagglutinin gene of PDV
PDV forward primer (nucleotide position
41–62a)
PDV probe (nucleotide position
64–78a)
PDV reverse primer (nucleotide position 101–123a)
DK881a(H)GGTGGGTGCCTTTTACAAGAAC DK881a(H)ATGCAAGGGCCAATT DK881a(H)GGACGAGGTTGAGGAAAGAAGAT
DK884a(H)GGTGGGTGCCTTTTACAAGAAC DK884a(H)ATGCAAGGGCCAATT DK884a(H)GGACGAGGTTGAGGAAAGAAGAT
4a(H) GGTGGGTGCCTTTTACAAGAAC 4a(H) ATGCAAGGGCCAATT 4a(H) GGACGAGGTTGAGGAAAGAAGAT
(H) GGTGGGTGCCTTTTACAAGAAC (H) ATGCAAGGGCCAATT (H) GGACGAGGTTGAGGAAAGAAGAT
********************** *************** ***********************
Primer GGTGGGTGCCTTTTACAAGAAC Probe ATGCAAGGGCCAATT Primer ATCTTCTTTCCTCAACCTCGTCC
aNumbering according to Nielsen (2002), where the ATG start codon for the haemagglutinin gene is located at nucleotide position 21 [7]
Primer–probe sequences are presented in the 5′ to 3′ orientation
Table 1 Multiple sequence alignment for hepatitis C virus (HCV)-specific primer–probe set for the 5′UTR of HCV genotypes
HCV forward primer (nucleotide position
74–92a)
HCV-MGB probe (nucleotide position
147–164a)
HCV reverse primer (nucleotide position
288–308a)
HCV1a AGCGTCTAGCCATGGCGTT HCV1a TCTGCGGAACCGGTGAGT HCV1a ACTGCCTGATAGGGTGCTTGC
HCV1b AGCGTCTAGCCATGGCGTT HCV1b TCTGCGGAACCGGTGAGT HCV1b ACTGCCTGATAGGGTGCTTGC
HCV1c AGCGTCTAGCCATGGCGTT HCV1c TCTGCGGAACCGGTGAGT HCV1c ACTGCCTGATAGGGTGCTTGC
HCV2a AGCGTCTAGCCATGGCGTT HCV2a TCTGCGGAACCGGTGAGT HCV2a ACTGCCTGATAGGGTGCTTGC
HCV2b AGCGTCTAGCCATGGCGTT HCV2b TCTGCGGAACCGGTGAGT HCV2b ACTGCCTGATAGGGTGCTTGC
HCV2c AGCGTCTAGCCATGGCGTT HCV2c TCTGCGGAACCGGTGAGT HCV2c ACTGCCTGATAGGGTGCTTGC
HCV3a AGCGCCTAGCCATGGCGTT HCV3a TCTGCGGAACCGGTGAGT HCV3a ACTGCCTGATAGGGTGCTTGC
HCV3b AGCGTCTAGCCATGGCGTT HCV3b TCTGCGGAACCGGTGAGT HCV3b ACTGCCTGATAGGGTGCTTGC
HCV4a AGCGTCTAGCCATGGCGTT HCV4a TCTGCGGAACCGGTGAGT HCV4a ACTGCCTGATAGGGTGCTTGC
HCV4b AGCGTCTAGCCATGGCGTT HCV4b TCTGCGGAACCGGTGAGT HCV4b ACTGCCTGATAGGGTGCTTGC
HCV4c AGCGTCTAGCCATGGCGTT HCV4c TCTGCGGAACCGGTGAGT HCV4c ACTGCCTGATAGGGTGCTTGC
HCV4d AGCGTCTAGCCATGGCGTT HCV4d TCTGCGGAACCGGTGAGT HCV4d ACTGCCTGATAGGGTGCTTGC
HCV4e AGCGTCTAGCCATGGCGTT HCV4e TCTGCGGAACCGGTGAGT HCV4e ACTGCCTGATAGGGTGCTTGC
HCV4f AGCGTCTAGCCATGGCGTT HCV4f TCTGCGGAACCGGTGAGT HCV4f ACTGCCTGATAGGGTGCTTGC
HCV5a AGCGTCTAGCCATGGCGTT HCV5a TCTGCGGAACCGGTGAGT HCV5a ACTGCCTGATAGGGTGCTTGC
HCV6a AGCGTCTAGCCATGGCGTT HCV6a TCTGCGGAACCGGTGAGT HCV6a ACTGCCTGATAGGGTGCTTGC
**** ************** ****************** *********************
Primer AGCGTCTAGCCATGGCGTT Probe TCTGCGGAACCGGTGAGT Primer GCAAGCACCCTATCAGGCAGT
aNumbering according to Wang et al. (1993), where the ATG start codon for the polyprotein precursor gene is located at nucleotide position 342 [6]
Primer–probe sequences are presented in the 5′ to 3′ orientation
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assay was monitored by testing the HCV RNA Genotype
Panel for Nucleic Acid Amplification Techniques (NIBSC
code 02/202). To determine reproducibility, clinical samples
(n=32), the WHO dilution series and the QCMD panels
were tested in three separate assay runs using the same
batches of reagents.
The singleplex assay was evaluated by comparing the
results obtained for 200 serum samples (99 HCV-positive,
nine HCV-low-positive and 92 HCV-negative) with results
obtained from the COBAS AMPLICOR assay. An HCV-
low-positive sample was defined as a sample which yielded
an equivocal HCV result (absorbance at 660 nm≥0.15<1.0)
on initial testing and subsequently demonstrated absorbance
values≥0.15 on repeat testing in duplicate. The results of
the nine HCV-low-positive samples were also compared
with the results obtained by the VERSANT® HCV RNA
assay v3.0 (Bayer Diagnostics, Berkeley, CA). The multi-
plex assay was evaluated by testing representative samples
from the clinical trial group (n=28). A sample was
considered as a true positive/negative if an HCV-positive/-
negative result, respectively, was obtained by the COBAS
AMPLICOR assay.
Results
HCV cycle threshold (Ct) values for the ABI 6100 RNA
extracts (mean=36.0) were within one Ct value of those
obtained from UltraSens™ extracts (mean=35.2), with a
95% confidence interval (CI) of 0.6 to 0.9 (P<0.001). In the
singleplex assay, Ct values for HCV- and PDV-positive
signals ranged from 22.5–42.5 and 35.7–39.3, respectively.
Using a dilution series of the WHO Standard for HCV, the
LOD was determined as 100 IU/ml (Table 3). In accordance
with the qualitative QCMD rating, the assay achieved a
maximum performance score for QCMD HCV Proficiency
Panels 2002 and 2004 (Table 4). All HCV genotypes in the
HCV RNA Genotype Panel for Nucleic Acid Amplification
Techniques were detected (Table 3). The singleplex assay
also displayed good reproducibility with the results for
clinical samples (n=32), the WHO dilution series and the
QCMD panels, falling within 1.5 Ct values of each other.
In the singleplex assay, 107 of the 108 HCV-positive
samples tested yielded a positive result, thereby, demonstrat-
ing a sensitivity of 99.0%. The resulting negative predictive
value was 98.9%. The positive sample that remained
undetected in the clinical trial had previously failed to be
detected by the VERSANT® assay (LOD<3,200 copies/ml),
but yielded a positive result by the COBAS assay
(LOD=50 IU/ml), albeit within the low-positive category, as
defined above. All 92 HCV-negative samples in the clinical
trial yielded a negative result. The specificity and positive
predictive value for the singleplex assay were, therefore,
100%.
In the multiplex assay, Ct values for HCV-positive
signals demonstrated a wider range than the singleplex
assay (22.0–48.5). HCV amplification plots demonstrated a
mean increase of 1.5 in Ct values (95% CI of 0.4–2.5, P=
0.01) compared to the singleplex assay. For PDV-positive
signals, the range of Ct values also widened (35.9–48.0),
with a mean increase of 3.6 in individual Ct values (95% CI
of 2.5–4.8, P<0.001) (Table 5). Nevertheless, using the
multiplex format, the PDV internal control was detected in
all samples. The LOD of the multiplex assay was the same
as that observed for the singleplex assay (100 IU/ml). Of
the 28 HCV samples tested in multiplex, 27 yielded the
correct HCV result, with only one false-negative occurring.
This sample also yielded a false-negative result in the
singleplex assay.
Discussion
The direct detection of HCV RNA has become an essential
tool for the diagnosis of hepatitis C infection. The
qualitative RT-PCR assay developed demonstrated high
sensitivity (99.0%) and an acceptable LOD of 100 IU/ml,
which is comparable to other in-house HCV PCR detection
assays [8, 9]. This LOD falls within the recommended
detection limits for HCV RNA assays (100 IU/ml) [10],
although many commercial assays have a claimed an LOD
of 50 IU/ml. Only one of 108 HCV-positive samples tested
in the clinical trial was missed. This sample was undetected
in the VERSANT assay, which has an LOD value of <3,200
copies/ml. However, since the sample demonstrated a low-
positive result by the COBAS AMPLICOR system, which
has an LOD of 50 IU/ml, it is likely to represent a true
positive with a low viral load.
The assay also displayed excellent specificity, with the
detection of all genotypes in the NIBSC HCV RNA
Genotype Panel and the QCMD HCV Proficiency Panels
Table 3 Observed cycle threshold (Ct) values for dilution series of
HCV RNA WHO Standard (Panel A) and HCV genotype panel
(NIBSC) (Panel B)
Panel A Panel B
Standard (IU/ml) Observed Ct Genotype
1,000 IU/mL
Observed Ct
10,000 31.2 1 37.0
5,000 32.4 2 35.2
1,000 34.6 3 36.8
500 35.2 4 36.4
250 36.2 5 36.5
100 37.2 6 38.4
50 Undetected
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2002 and 2004. Using the singleplex assay, full marks were
obtained for both panels. In addition to high sensitivity and
specificity, the hybridisation probe assay yielded highly
reproducible results, with results not varying by more than
1.5 Ct values on repeat testing.
Although the HCV results of samples tested in multiplex
remained unchanged from the singleplex assay, the Ct values
of HCVand PDV target increased in the multiplex format. The
reason for this Ct increase is currently unknown, but may be
due to primer limitation or primer–dimer formation. Never-
theless, the multiplex assay yielded sensitivity (95.8%),
specificity (100%) and LOD (100 IU/ml) rates similar to the
singleplex assay. Preliminary results of the multiplex clinical
trial are promising and indicate that this assay may be used for
the qualitative detection of HCV.
It is increasingly recognised that the use of a universal
internal control helps to enhance the performance of
molecular virology techniques [11, 12]. This study, there-
fore, incorporated the design of a second RT-PCR assay for
the detection of a viral RNA internal control. PDV was
added directly to the samples in low concentration as a viral
substrate. As PDV behaves in a more similar manner to the
HCV target, it can simulate the extraction, amplification
and detection of HCV. This methodology confirmed that
there was no significant loss of sample during the extraction
procedure and that there were no inhibitors to reverse
transcription or amplification in the samples. International
collaboration among diagnostic laboratories to implement
PDV as a universal RNA viral internal control could
represent a step towards the standardisation of molecular
virology assays [11].
Aside from the design of an accurate HCV detection
assay, this study also addressed other important design
facets of molecular diagnostic assays. Many nucleic acid
extraction systems are designed for dedicated commercial
assays, but offer little flexibility for in-house assay design.
This study incorporated the development of a high-yield,
high-purity HCV RNA extraction method using the semi-
automated ABI PRISM™ 6100 Nucleic Acid PrepStation
Table 5 Comparison of cycle threshold (Ct) values observed for
HCV and PDV target in the singleplex and multiplex assays
Sample no. Singleplex
HCV Ct
Multiplex
HCV Ct
Singleplex
PDV Ct
Multiplex
PDV Ct
1 34.0 34.1 37.7 42.2
2 34.0 33.4 37.1 47.4
3 37.3 39.6 37.4 47.0
4 37.9 42.3 37.3 45.9
5 40.1 45.9 37.2 43.3
6 40.9 48.5 38.2 47.4
7 40.7 45.5 37.9 38.6
8 25.3 24.7 36.8 38.4
9 22.5 22.1 36.0 37.4
10 22.8 22.0 35.9 36.5
11 24.7 23.8 38.7 39.9
12 25.5 24.7 36.9 37.5
13 22.5 23.5 37.1 37.8
14 22.8 23.5 37.6 37.7
15 23.1 23.8 36.1 35.9
16 24.4 25.2 36.3 36.8
17 22.9 23.9 37.4 44.1
18 42.5 38. 39.3 43.3
19 38.8 39.1 35.9 48.4
20 36.7 38.3 37.1 48.0
21 40.8 47.1 37.2 43.6
22 36.1 37.2 36.8 38.9
23 36.6 39.5 35.7 37.9
24 35.1 35.5 36.1 40.1
25 37.3 40.0 36.4 38.1
26 Undetected Undetected 35.8 37.7
27 Undetected Undetected 37.6 39.9
28 Undetected Undetected 37.3 39.4
Mean 31.7 33.1 37.0 40.7
Standard
deviation
7.8 9.5 0.9 3.8
95% lower–
95% upper
0.4–2.5 2.5–4.8
Table 4 Observed cycle threshold (Ct) values for QCMD HCV proficiency panels
QCMD 2002 Target concentration range (IU/mL) Observed Ct QCMD 2004 Target concentration (IU/mL) Observed Ct
HCV 1 2–20×104 (+)a 30.5 (+) HCV 17 8.3×103 (+) 32.2 (+)
HCV 2 1–4×105 (+) 27.2 (+) HCV 18 1.7×103 (+) 33.3 (+)
HCV 3 BLDb-1,200 (+) 39.5 (+) HCV 19 1.7×102 (+) 39.0 (+)
HCV 4 1–5×104 (+) 30.9 (+) HCV 20 8.3×104 (+) 28.5 (+)
HCV 5 1–8×103 (+) 37.2 (+) HCV 21 8.3×103 (+) 31.5 (+)
HCV 6 1–8×03 (+) 36.4 (+) HCV 22 3.4×103 (+) 33.2 (+)
HCV 7 BLD-1,200 (+) Undetected (–) HCV 23 8.3×104 (+) 26.8 (+)
HCV 8 Neg (−)c Undetected (–) HCV 24 Negative (−) Undetected (−)
a (+)=positive signal
b BLD=below limit of detection
c (−),=negative signal
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(Applied Biosystems, Foster City, CA). This system
enabled rapid high-throughput purification, thus, helping to
overcome the cost issues associated with automation and the
time factors associated with manual extraction procedures.
The lack of PCR inhibitors observed in this study reflects the
high purity of viral RNA isolated using the optimised semi-
automated ABI 6100 extraction protocol. Furthermore, the
results for the ABI 6100 extracts compared well to the results
for extracts from the manual UltraSens™ Kit.
The HCV assay developed in this study represents a
robust and reliable RT-PCR method for the detection of
hepatitis C in serum samples. The assay design incorporat-
ed the use of semi-automated extraction, a viral substrate
internal control, a two-step RT-PCR procedure and a
flexible singleplex or multiplex format and represents an
attractive alternative to commercial HCV PCR systems.
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